

SECTION-1: Identification of the substance / mixture and the company / undertaking

Catalogue Number	CS-ER-03085
Product Name	Elacestrant
CAS No.	722533-56-4
Category	API
Synonyms	(R)-6-(2-(ethyl(4-(2-(ethylamino)ethyl)benzyl)amino)-4-methoxyphenyl)-5,6,7,8-tetrahydro-2H-chromeno[2,3-b]pyridine-2-ol
Brand	Clearsynth Labs Ltd.
Identified uses	Laboratory Chemicals
Uses advised against	Not available
Company	Clearsynth Labs Ltd. Mumbai, India
Emergency Phone #	+91-22-245045900
REACH No.	Not available

SECTION 2: Hazards identification

Disclaimer: This is sample MSDS. Please email sales@clearsynth.com for more details.

2.1 Classification of the substance or mixture-Regulation (EC) No 1272/2008:

Not available

2.2 Label Elements

Signal Word: Not available

Not available

Hazard Statement(s)

Code	Statement
Not available	Not available

Precautionary Statement(s)

Code	Statement
Not available	Not available

SECTION 3: Composition / information on ingredients

3.1 Substance

Component : Elacestrant

CAS Number : 722533-56-4

Molecular Formula : C₃₀H₃₈N₂O₂

Molecular Weight : 458.63

Parent Chemical : Elacestrant

Synonyms :

(R)-6-(2-(ethyl(4-(2-(ethylamino)ethyl)benzyl)amino)-4-methoxyphenyl)-5,6,7,8-tetrahydronaphthalen-2-ol

Concentration : Not available

SECTION 4: First aid measures

Not available

SECTION 5: Firefighting measures

Not available

SECTION 6: Accidental release measures

Not available

SECTION-7: Handling and storage

Not available

SECTION 8: Exposure controls / personal protection

Not available

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Test	Result
Appearance	No data available
IR spectrum	No data available
pH	No data available
Solubility	No data available

Property	Value
a) Physical State	No data available
b) Color	No data available
c) Odor	No data available
d) pH	No data available
e) Vapour Pressure	No data available
f) Viscosity	No data available
g) Initial Boiling Point and boiling range	No data available
h) Melting Point / Freezing Point	No data available
i) Auto Ignition Temperature	No data available
j) Flash Point	No data available
k) Explosion Limit, Lower	No data available
l) Explosion Limit, Upper	No data available
m) Decomposition Temperature	No data available
n) Loss on Drying	No data available
o) Relative Density	No data available
p) Solubility (in DMSO)	No data available
q) Oxidizing Properties	No data available

SECTION 10: Stability and reactivity

Not available

SECTION 11: Toxicological information

11.1 Information on toxicological effects

- Acute toxicity: In the major registration trial of elacestrant as therapy of breast cancer, serum ALT elevations arose in similar proportions of those on elacestrant as of the controls receiving "standard of care" (9% vs 10%) and were above 5 times the upper limit of normal in 2.1% vs 0.9% of controls. The elevations were transient and without symptoms or jaundice. No patient developed clinically apparent liver injury. Since its approval and more widespread use, there have been no published reports of hepatotoxicity attributed to elacestrant therapy. Likelihood score: E (unlikely cause of clinically apparent liver injury).

- Skin corrosion/irritation: No data available.
- Serious eye damage/eye irritation: No data available.
- Respiratory or skin sensitization: No data available.

- Germ cell mutagenicity: No data available.
- Carcinogenicity: In the major registration trial of elacestrant as therapy of breast cancer, serum ALT elevations arose in similar proportions of those on elacestrant as of the controls receiving “standard of care” (9% vs 10%) and were above 5 times the upper limit of normal in 2.1% vs 0.9% of controls. The elevations were transient and without symptoms or jaundice. No patient developed clinically apparent liver injury. Since its approval and more widespread use, there have been no published reports of hepatotoxicity attributed to elacestrant therapy. Likelihood score: E (unlikely cause of clinically apparent liver injury).
- Reproductive toxicity: No data available.
- STOT-single exposure: No data available.
- STOT-repeated exposure: No data available.
- Aspiration hazard: No data available.

Likely routes of exposure

- No data available.

Symptoms related to the physical, chemical and toxicological characteristics

- In the major registration trial of elacestrant as therapy of breast cancer, serum ALT elevations arose in similar proportions of those on elacestrant as of the controls receiving “standard of care” (9% vs 10%) and were above 5 times the upper limit of normal in 2.1% vs 0.9% of controls. The elevations were transient and without symptoms or jaundice. No patient developed clinically apparent liver injury. Since its approval and more widespread use, there have been no published reports of hepatotoxicity attributed to elacestrant therapy. Likelihood score: E (unlikely cause of clinically apparent liver injury).

SECTION 12: Ecological information

Not available

SECTION 13: Disposal considerations

Not available

SECTION 14: Transport information

Not available

SECTION 15: Regulatory information

Not available

SECTION 16: Other information

Not available

DISCLAIMER

This MSDS is system-generated. Please verify and confirm all data, statements, and values with the Support Team before use or distribution.